BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37607457)

  • 1. Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.
    Versluis J; Saber W; Tsai HK; Gibson CJ; Dillon LW; Mishra A; McGuirk J; Maziarz RT; Westervelt P; Hegde P; Mukherjee D; Martens MJ; Logan B; Horowitz M; Hourigan CS; Nakamura R; Cutler C; Lindsley RC;
    J Clin Oncol; 2023 Oct; 41(28):4497-4510. PubMed ID: 37607457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes.
    Wang W; Auer P; Zhang T; Spellman S; Carlson KS; Nazha A; Bolon YT; Saber W
    Transplant Cell Ther; 2021 Aug; 27(8):659.e1-659.e6. PubMed ID: 33992829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome.
    Park S; Baek DW; Sohn SK; Ahn JS; Kim HJ; Shin HJ; Chung JS; Lee SM; Lee WS; Lim SN; Lee YJ; Choi Y; Lee HS; Cho YY; Lee GW; Moon JH
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e367-e373. PubMed ID: 31060990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.
    Heuser M; Gabdoulline R; Löffeld P; Dobbernack V; Kreimeyer H; Pankratz M; Flintrop M; Liebich A; Klesse S; Panagiota V; Stadler M; Wichmann M; Shahswar R; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Geffers R; Schlegelberger B; Göhring G; Kreipe HH; Germing U; Ganser A; Kröger N; Koenecke C; Thol F
    Ann Hematol; 2017 Aug; 96(8):1361-1372. PubMed ID: 28612220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
    Lindsley RC; Saber W; Mar BG; Redd R; Wang T; Haagenson MD; Grauman PV; Hu ZH; Spellman SR; Lee SJ; Verneris MR; Hsu K; Fleischhauer K; Cutler C; Antin JH; Neuberg D; Ebert BL
    N Engl J Med; 2017 Feb; 376(6):536-547. PubMed ID: 28177873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome.
    Kim YJ; Jung SH; Hur EH; Choi EJ; Lee KH; Yim SH; Kim HJ; Kwon YR; Jeon YW; Lee SH; Chung YJ; Lee JH
    Leuk Res; 2018 Nov; 74():97-104. PubMed ID: 30343213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.
    Bejar R; Stevenson KE; Caughey B; Lindsley RC; Mar BG; Stojanov P; Getz G; Steensma DP; Ritz J; Soiffer R; Antin JH; Alyea E; Armand P; Ho V; Koreth J; Neuberg D; Cutler CS; Ebert BL
    J Clin Oncol; 2014 Sep; 32(25):2691-8. PubMed ID: 25092778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Marvin-Peek J; Mason EF; Kishtagari A; Jayani RV; Dholaria B; Kim TK; Engelhardt BG; Chen H; Strickland S; Savani B; Ferrell B; Kassim A; Savona M; Mohan S; Byrne M
    Transplant Cell Ther; 2023 Jun; 29(6):390.e1-390.e10. PubMed ID: 36906277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The prognostic significance of pretransplantation evaluation of IPSS-R and WPSS in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation].
    Lu CQ; Hou C; Wang P; Zhang LW; Fan Y; Wu DP; Xu Y
    Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):247-254. PubMed ID: 35405784
    [No Abstract]   [Full Text] [Related]  

  • 12. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Outcomes of 138 myelodysplastic syndrome patients with HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation].
    Wang QQ; Liu ZX; Zhao XL; Zhang GX; Yao JF; Zheng XH; Zhang LN; Shen YY; Zhao XL; He Y; Huang Y; Zhang RL; Wei JL; Ma QL; Pang AM; Yang DL; Zhai WH; Jiang EL; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):132-137. PubMed ID: 32135630
    [No Abstract]   [Full Text] [Related]  

  • 14. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.
    Nazha A; Hu ZH; Wang T; Lindsley RC; Abdel-Azim H; Aljurf M; Bacher U; Bashey A; Cahn JY; Cerny J; Copelan E; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla SM; Gale RP; George B; Gergis U; Grunwald MR; Hamilton B; Hashmi S; Hildebrandt GC; Inamoto Y; Kalaycio M; Kamble RT; Kharfan-Dabaja MA; Lazarus HM; Liesveld JL; Litzow MR; Majhail NS; Murthy HS; Nathan S; Nishihori T; Pawarode A; Rizzieri D; Sabloff M; Savani BN; Schachter L; Schouten HC; Seo S; Shah NN; Solh M; Valcárcel D; Vij R; Warlick E; Wirk B; Wood WA; Yared JA; Alyea E; Popat U; Sobecks RM; Scott BL; Nakamura R; Saber W
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2139-2146. PubMed ID: 32781289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythroid nuclear dysplasia is associated with inferior outcomes for patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation.
    Chen EC; Li S; Yang J; Zhang ML; Hasserjian R; Chen YB; Brunner AM; DeFilipp Z
    Leuk Res; 2021 Oct; 109():106625. PubMed ID: 34062365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.
    Christopeit M; Badbaran A; Alawi M; Zabelina T; Zeck G; Wolschke C; Ayuk F; Kröger N
    Eur J Haematol; 2016 Sep; 97(3):288-96. PubMed ID: 26680262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation.
    Yalniz FF; Greenbaum U; Pasvolsky O; Milton DR; Kanagal-Shamanna R; Ramdial J; Srour S; Mehta R; Alousi A; Popat UR; Nieto Y; Kebriaei P; Al-Atrash G; Oran B; Hosing C; Ahmed S; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
    Transplant Cell Ther; 2024 Feb; 30(2):205.e1-205.e12. PubMed ID: 37437764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy.
    Zuanelli Brambilla C; Lobaugh SM; Ruiz JD; Dahi PB; Goldberg AD; Young JW; Gyurkocza B; Shaffer BC; Ponce DM; Tamari R; Sanchez Escamilla M; Castillo Flores N; Politikos I; Scordo M; Shah GL; Cho C; Lin RJ; Maloy MA; Devlin SM; Jakubowski AA; Berman E; Stein EM; Papadopoulos EB; Perales MA; Tallman MS; Giralt SA; Smith M
    Transplant Cell Ther; 2021 Sep; 27(9):771.e1-771.e10. PubMed ID: 34033977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.